Video

VIDEO: Multidisciplinary panel addresses role of anesthesia, analgesics in patient outcomes


 

AT SABCS 2014

References

SAN ANTONIO – As follow-up to “Does choice of anesthesia set up your patient for metastasis?” published in the September issue, the Oncology Report brought together an anesthesiologist, a breast surgeon, a medical oncologist, and a patient advocate at the San Antonio Breast Cancer Symposium to further discuss the topic. The issue was first raised following publication of a retrospective study in 2006, which showed a 40% reduction in recurrence in women given a type of regional anesthesia, with general anesthesia, rather than general anesthesia and postoperative morphine anesthesia during primary breast cancer surgery.

Dr. William J. Gradishar, Betsy Bramsen Professor of Breast Oncology at Northwestern University, Chicago, moderated the discussion with Dr. Juan Cata, assistant professor in the department of anesthesiology and perioperative medicine at the University of Texas MD Anderson Cancer Center, Dr. Susan Love, breast surgeon, and president and medical director of the Dr. Susan Love Research Foundation, and Musa Mayer, author and patient advocate.

The panel addressed the impact of surgery alone, anesthesia during surgery, and perioperative analgesics on patients’ immune functioning and ultimately disease outcomes. The state of the evidence in breast cancer and other tumor types, and an ongoing prospective trial with breast cancer patients, were also discussed.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

lnikolaides@frontlinemedcom.com

On Twitter @nikolaideslaura

Recommended Reading

Mastectomies, reconstruction, on the rise for women with early stage disease
MDedge ObGyn
Breast cancer relapse risk halved since 1986
MDedge ObGyn
Too many elderly with breast cancer still receive radiotherapy
MDedge ObGyn
Ultrasound screening for dense breasts is high cost, offers little benefit
MDedge ObGyn
Pictilisib plus fulvestrant boosts PFS in ER/PR+ patients
MDedge ObGyn
VIDEO: Is there a future for pictilisib in the treatment of HR+ breast cancer?
MDedge ObGyn
Pembrolizumab shows efficacy in advanced triple-negative breast cancer patients
MDedge ObGyn
VIDEO: High TILs associated with less efficacy from trastuzumab
MDedge ObGyn
North America has highest rate of obesity-related cancers
MDedge ObGyn
Adjuvant capecitabine adds no advantage to bisphosphonate in elderly breast cancer patients
MDedge ObGyn